Paige

Paige builds AI-based digital pathology software including the first FDA-approved AI for prostate cancer detection in whole-slide imaging, plus a cloud-based pathology viewer. FDA approval for Paige Prostate. Raised $220M+. Spun out of Memorial Sloan Kettering Cancer Center. Partnerships with Microsoft for cloud-scale pathology AI.

Paige achieved the first FDA approval for AI-based cancer detection in whole-slide pathology imaging — a regulatory first that opened the category for digital pathology AI diagnostics.

paige.ai Pathology AI

United Statesprivate

At a glance

Total raised

$296.3M

last round acquired

Headcount

51-200

approximate · public range

Headquarters

New York

United States

Founded

2017

9 years active

Status

Private

Pathology AI

Patents on file

USPTO grants

For subscribers

Subscribe to see the full profile

Including Funding rounds, Bull / Bear thesis, Stock + earnings, Roster changes, Patents, News, and Open roles.

Founding

50% off

/month

94 of 100 spots left

Full

$10

/month

Available once all 100 Founding Member spots are claimed.

Get full access

Already subscribed? Sign in →

Funding history

Total raised

$296.3M

Rounds tracked

Latest stage

Acquired

Date	Stage	Amount	Valuation	Lead investors
Aug 22, 2025	Acquired	$81.3M	—	Tempus AI
Mar 9, 2021	Series C	$25M	—	KKR
Jan 14, 2021	Series C	$100M	—	Casdin Capital, Johnson & Johnson Innovation – JJDC
Jul 13, 2020	Series B	$20M	—	Goldman Sachs, Healthcare Venture Partners
Dec 18, 2019	Series B	$45M	—	Healthcare Venture Partners
Feb 5, 2018	Series A	$25M	—	Breyer Capital

Founder backgrounds

David Klimstra

Co-Founder (former)

A pathologist with more than three decades at Memorial Sloan Kettering Cancer Center, where he served as Chair of the Department of Pathology. Klimstra received his MD and completed his residency in anatomic pathology at Yale, followed by a fellowship in oncologic surgical pathology at MSK. His research on GI, liver, and pancreatic tumors — particularly precursors to pancreatic cancer — provided the clinical foundation for Paige, which he co-founded with MSK colleagues in 2017. He served as the company's Chief Medical Officer from 2021 to 2024 before returning to Yale as Professor of Pathology. Paige went on to secure the first FDA approval for an AI product in digital pathology.

Thomas Fuchs

Chief Scientist (former)

Holds a doctorate in machine learning from ETH Zurich and a master's in technical mathematics from Graz Technical University. Before founding Paige, Fuchs directed the Computational Pathology laboratory at Memorial Sloan Kettering Cancer Center, where the company's technology was incubated before spinning out in 2018. Earlier in his career, he built AI systems for Mars rovers at NASA's Jet Propulsion Laboratory. He is also the Dean of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai and, since 2024, serves as Chief AI Officer at Eli Lilly — a rare case of a founder taking a senior AI role at a major pharmaceutical company after building a diagnostic AI startup.

AI bull / bear

Bull case

Paige holds a regulatory first-mover advantage that is difficult to replicate. Its FDA authorization for AI-based prostate cancer detection in whole-slide imaging required years of clinical validation and a de novo pathway that competitors must now match — a multi-year undertaking. The Memorial Sloan Kettering provenance supplies both algorithmic credibility and access to one of the world's largest annotated pathology archives, which compounds into better model performance over time. The Microsoft partnership embeds Paige's tools into Azure's healthcare cloud, giving it an enterprise distribution channel that no pure-play pathology AI startup can match. With $296 million in total capital raised and the 2025 Tempus AI transaction, Paige gains access to Tempus's vast multimodal oncology dataset and existing hospital relationships. Together they can bundle pathology AI with genomic profiling and clinical decision support, creating a full-stack oncology intelligence platform that drives adoption through workflow integration rather than standalone point-solution sales.

Bear case

The Tempus AI deal raises uncomfortable questions. Paige raised $296 million across its life as an independent company, yet the August 2025 transaction was valued at just $81 million — a steep discount that suggests the standalone business struggled to find product-market fit at scale. If this was an acquisition rather than a growth round, early investors may have been wiped out, implying the core technology could not command a premium on its own. Digital pathology adoption remains the bottleneck the company cannot control. Despite the regulatory green light, most labs still operate glass-slide workflows. Converting them requires capital expenditure on scanners, IT infrastructure, and workflow redesign — a multi-year cycle that Paige cannot accelerate. Meanwhile, Roche, Philips, and other diagnostics incumbents are building their own AI pathology modules integrated directly into their scanning hardware. Paige risks becoming a feature absorbed into someone else's platform rather than a standalone category-defining company.

Generated by deepseek-v4-pro · May 2, 2026Refreshes quarterly · see disclosures

In the news

Paige · last 30 days

No articles ingested yet for Paige. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.

Watch

Leadership

Thomas Fuchs

Chief Scientist (former)

David Klimstra

Co-Founder (former)

—

Products

Paige Prostate Suite
An AI-powered diagnostic suite that aids pathologists in detecting and grading prostate cancer on H&E-stained whole-slide images of prostate needle biopsies. Paige Prostate Detect was the first AI-based pathology software to receive FDA approval for assisting in the primary diagnosis of prostate cancer. The suite improves diagnostic accuracy across experience levels by automatically analyzing slides and flagging suspicious regions for pathologist review.
Paige Breast Suite
A set of AI applications designed to support pathologists in the identification and classification of breast cancer on H&E-stained whole-slide images from breast biopsy and excision specimens. The suite helps pathologists detect suspicious lesions and classify cancer subtypes, improving workflow efficiency and diagnostic confidence in breast pathology.
Paige GI Suite
A portfolio of AI-powered applications that support pathologists in the detection and classification of cancers in gastrointestinal tissue samples. The suite brings Paige's proven AI technology to GI pathology, helping pathologists identify suspicious regions and reduce diagnostic turnaround times.
FullFocus
An FDA-cleared whole-slide image viewer that enables pathologists to view, manage, and share digital slides of tissue samples for primary diagnosis. FullFocus is vendor-neutral and integrates with various scanners and LIS applications, providing robust diagnostic tools, AI visualization overlays, and collaboration features that unlock digital pathology's full potential in clinical workflows.
Virchow
A large foundation model for pathology trained on over 2.3 million whole-slide images spanning hundreds of thousands of patient cases. Virchow is available under an open-source license and provides a powerful base for developing AI applications across multiple cancer types. It enables researchers and developers to build upon Paige's extensive pathology dataset for novel diagnostic tools and biomarker discovery.

Most recent patents

Paige Electric Company, LP·2024-11-12
Cable For Power-Over-Ethernet Having An Extended Usable Length
US12142389
Abstract
Cable For Power-Over-Ethernet Having An Extended Usable Length
US12142389
Abstract A method of extending the usable length of a power-over-ethernet cable includes the steps of providing twisted pairs of wires with the conductor of each wire being a 20 AWG or 22 AWG conductor and terminating the cable at an RJ-45 style connector. The connector for the 20 AWG conductors has an insert therein with holes that can accommodate 20 AWG conductors. FEP, PVC or PP insulation may surround each conductor.
View on Google Patents

Open roles

We don't have a live feed for this company's ATS. Their careers page has every open role.

View all careers ↗

Compare Paige with

vs Pathology AI
Paige vs PathAI